Filipendula ulmaria In 1897, Felix Hoffmann created a synthetically altered version of salicin, derived from the species, which caused less digestive upset than pure salicylic acid. The new drug, formally acetylsalicylic acid, was named aspirin by Hoffmann's employer Bayer AG after the old botanical name for meadowsweet, "Spiraea ulmaria". This gave rise to the class of drugs known as non-steroidal anti-inflammatory drugs (NSAIDs). A natural black dye can be obtained from the roots by using a copper mordant. A tea made from "Filipendula ulmaria" flowers or leaves has been used in traditional Austrian herbal medicine for the treatment of rheumatism, gout, infections,
Mycophenolic acid studies have found it inferior to azathioprine. A combination of mycophenolate and ribavirin has been found to stop infection by and replication of dengue virus "in vitro". Mycophenolic acid Mycophenolic acid, also called mycophenolate, is an immunosuppressant drug used to prevent rejection in organ transplantation. It was initially marketed as the prodrug mycophenolate mofetil (MMF) to improve oral bioavailability. More recently, the salt mycophenolate sodium has also been introduced. Mycophenolate mofetil is marketed under the trade name CellCept and mycophenolate sodium as Myfortic. Discovered by an Italian medical scientist Bartolomeo Gosio in 1893, mycophenolic acid was the first antibiotic to